ArticleCureus2026
Detection of Cytomegalovirus in Patients Attending a Tertiary Care Center: A Retrospective Analysis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Human cytomegalovirus (CMV) is a DNA β-herpesvirus that establishes lifelong latency in bone marrow-derived CD34+ progenitors and CD14+ monocytes following primary infection. The virus restricts gene expression to prevent replication but reactivates when these cells differentiate into macrophages or dendritic cells, often triggered by inflammation or immunosuppression, and causes significant morbidity. Congenital CMV remains a major global health issue and the leading cause of non-genetic neurodevelopmental impairment worldwide. Compared to seroprevalence studies, fewer studies have evaluated active CMV infection using molecular methods. Quantitative real-time polymerase chain reaction (qPCR)-based detection of CMV DNA provides a reliable measurement of active infection and viral burden. Objectives This study was conducted to assess the prevalence, demographic characteristics, and viral load distribution of CMV and to evaluate its clinical spectrum and association with underlying diseases in patients with suspected infection. Materials and methods This retrospective analysis was conducted at a tertiary care hospital in Chennai, India, involving 162 patients who were tested from January 2024 to June 2024. Viral DNA was extracted using spin-column extraction kits (Qiagen Blood Mini-kits). CMV DNA detection and quantification were performed using a TaqMan-based real-time PCR assay (Thermo Fisher Scientific, Waltham, MA, USA), targeting the CMV ppUL83 gene on a Rotor-Gene-Q instrument (Qiagen, Hilden, Germany). The lower limit of detection was 50 copies/mL. Results In our study, CMV DNA was detected in 43 (26.5%) of the 162 patients. Among the CMV-positive patients, age and gender showed no significant association. Preterm birth was noted in 12 (27.9%) patients. Immunocompromised individuals showed a significant association with CMV positivity; among these, seven (16.3%) patients were transplant recipients, and five (11.6%) patients had hematological malignancies. Gastrointestinal manifestations were the most common presenting feature, seen in 22 (51.1%) patients. Of the 43 CMV-positive individuals, 23 (53.5%) had viral loads ranging from 50 to 10,000 viral DNA copies/mL. Conclusion CMV infection represents a significant health burden in tertiary care settings. This study highlights the role of qPCR in the early detection of active CMV infections. Early diagnosis allows timely initiation of antiviral therapy and thereby improves clinical outcomes, particularly in immunocompromised individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.